Syndax Pharmaceuticals, Inc. (SNDX)
19.57
-0.08
(-0.41%)
USD |
NASDAQ |
Aug 24, 16:00
19.70
+0.13
(+0.66%)
Pre-Market: 20:00
Syndax Pharmaceuticals Net Income (Quarterly) : -49.36M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -49.36M |
| March 31, 2026 | -42.67M |
| December 31, 2025 | -68.01M |
| September 30, 2025 | -60.72M |
| June 30, 2025 | -71.85M |
| March 31, 2025 | -84.85M |
| December 31, 2024 | -94.17M |
| September 30, 2024 | -84.13M |
| June 30, 2024 | -68.06M |
| March 31, 2024 | -72.40M |
| December 31, 2023 | -72.47M |
| September 30, 2023 | -51.15M |
| June 30, 2023 | -44.62M |
| March 31, 2023 | -41.13M |
| December 31, 2022 | -39.19M |
| September 30, 2022 | -35.40M |
| June 30, 2022 | -37.57M |
| March 31, 2022 | -37.17M |
| December 31, 2021 | 96.20M |
| September 30, 2021 | -20.64M |
| June 30, 2021 | -22.91M |
| March 31, 2021 | -27.72M |
| December 31, 2020 | -20.42M |
| September 30, 2020 | -20.44M |
| Date | Value |
|---|---|
| June 30, 2020 | -17.06M |
| March 31, 2020 | -19.14M |
| December 31, 2019 | -14.00M |
| September 30, 2019 | -12.83M |
| June 30, 2019 | -14.92M |
| March 31, 2019 | -14.30M |
| December 31, 2018 | -18.84M |
| September 30, 2018 | -17.34M |
| June 30, 2018 | -18.39M |
| March 31, 2018 | -19.40M |
| December 31, 2017 | -19.10M |
| September 30, 2017 | -15.09M |
| June 30, 2017 | -13.64M |
| March 31, 2017 | -12.97M |
| December 31, 2016 | -10.82M |
| September 30, 2016 | -14.97M |
| June 30, 2016 | -8.358M |
| March 31, 2016 | -10.33M |
| September 30, 2014 | -10.86M |
| June 30, 2014 | |
| March 31, 2014 | -3.979M |
| December 31, 2013 | -2.494M |
| September 30, 2013 | |
| March 31, 2013 | 0.557M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Viking Therapeutics, Inc. | -128.02M |
| Kura Oncology, Inc. | -68.33M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 72.79M |
| Total Expenses (Quarterly) | 122.15M |
| EPS Diluted (Quarterly) | -0.5547 |
| Enterprise Value | 1.786B |
| Gross Profit Margin (Quarterly) | 95.59% |
| Profit Margin (Quarterly) | -67.82% |
| Earnings Yield | -12.87% |
| Normalized Earnings Yield | -12.87 |